| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 71610-0834-80 | 71610-0834 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 18, 2024 | In Use | |
| 00603-5338-32 | 00603-5338 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 12, 2002 | In Use | |
| 71335-1628-09 | 71335-1628 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 28, 2022 | In Use | |
| 68083-0462-10 | 68083-0462 | Arsenic Trioxide | Arsenic Trioxide | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Oct 7, 2021 | In Use | |
| 39822-0650-06 | 39822-0650 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Feb 17, 2025 | In Use | |
| 63187-0160-21 | 63187-0160 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 1, 2018 | In Use | |
| 70377-0012-22 | 70377-0012 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2021 | In Use | |
| 50090-1989-09 | 50090-1989 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 17, 2015 | In Use | |
| 00024-5917-01 | 00024-5917 | Clofarabine | Clolar | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jul 1, 2017 | Mar 31, 2019 | In Use |
| 57894-0080-90 | 57894-0080 | Lazertinib | LAZCLUZE | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug 20, 2024 | In Use | |
| 71335-2088-02 | 71335-2088 | PREDNISONE | Prednisone | 2.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 6, 2022 | In Use | |
| 73380-4700-01 | 73380-4700 | MOXETUMOMAB PASUDOTOX | LUMOXITI | 1.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | May 15, 2020 | In Use | |
| 68788-8433-09 | 68788-8433 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Apr 24, 2024 | In Use | |
| 63304-0044-22 | 63304-0044 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
| 64380-0782-06 | 64380-0782 | PREDNISONE | Prednisone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 1, 2021 | In Use | |
| 71335-2079-06 | 71335-2079 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 2, 2022 | In Use | |
| 47335-0083-50 | 47335-0083 | Doxorubicin Hydrochloride | Lipodox 50 | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb 9, 2012 | May 29, 2015 | In Use |
| 00015-3215-30 | 00015-3215 | Carboplatin | Paraplatin | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 1, 2008 | Apr 14, 2009 | In Use | |
| 00006-0461-02 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Mar 26, 2003 | In Use | |
| 59572-0710-30 | 59572-0710 | Enasidenib mesylate | Idhifa | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH2 | Oral | Aug 1, 2017 | In Use | |
| 68071-5221-01 | 68071-5221 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 27, 2020 | In Use | |
| 68382-0915-84 | 68382-0915 | Erlotinib | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 62135-0759-30 | 62135-0759 | Methylprednisolone | Methylprednisolone | 2.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 14, 2024 | In Use | |
| 60687-0386-94 | 60687-0386 | DRONABINOL | DRONABINOL | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Mar 31, 2024 | In Use | |
| 62856-0724-30 | 62856-0724 | Lenvatinib | Lenvima | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Feb 13, 2015 | In Use |
Found 11888 results — Export these results
Home